Literature DB >> 16751262

Structural characterization of anti-HIV drug candidate PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] and its acyl glucuronides in rat bile and evaluation of in vitro stability in human and animal liver microsomes and plasma.

Zhiming Wen1, Stephan T Stern, David E Martin, Kuo-Hsiung Lee, Philip C Smith.   

Abstract

PA-457 [3-O-(3',3'-dimethylsuccinyl)-betulinic acid] represents a new class of anti-HIV drug candidates termed maturation inhibitors. After oral administration to rats, PA-457 was metabolized to several glucuronide conjugates and mainly eliminated into rat bile. Liquid chromatography-electrospray ionization-mass spectrometry analysis showed that the glucuronidation products of PA-457 were acyl glucuronides including one di-glucuronide, di-PA-457G, and two mono-glucuronides, referred to as mono-PA-457G (I) and mono-PA-457G (II), respectively. In-source fragmentation of MS spectra supported the conclusion that mono-PA-457G (I) was glucuronidated at the C-28 carboxyl of PA-457, whereas mono-PA-457G (II) was conjugated at the dimethylsuccinic acid side chain of the C-3 position. Quantification demonstrated that the predominant glucuronide of PA-457 in rat bile was mono-PA-457G (I) with lower amounts of mono-PA-457G (II) and di-PA-457G. In vitro stability indicated that the mono-acyl glucuronides of PA-457 were not degraded after incubation with 0.1 M phosphate buffer (pH 4, 7.4 and 9), plasma (human, rat, and mouse), and UDP-glucuronosyltransferase reaction media (without uridine 5'-diphosphoglucuronic acid) with microsomes (human, rat, and mouse liver microsomes), respectively, whereas the minor diglucuronide was unstable in rodent liver microsomes. All glucuronides of PA-457 could be hydrolyzed both by beta-glucuronidase and alkaline (1 M NaOH). Minor putative acyl migration products were slowly formed at pH 9, suggesting that the acyl glucuronides of PA-457 have relatively high in vitro stability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16751262     DOI: 10.1124/dmd.106.009233

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

Review 1.  New approaches for antiviral targeting of HIV assembly.

Authors:  Peter E Prevelige
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

2.  Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers.

Authors:  David E Martin; Robert Blum; John Wilton; Judy Doto; Hal Galbraith; Gina L Burgess; Philip C Smith; Charles Ballow
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 3.  Virus maturation as a new HIV-1 therapeutic target.

Authors:  Catherine S Adamson; Karl Salzwedel; Eric O Freed
Journal:  Expert Opin Ther Targets       Date:  2009-08       Impact factor: 6.902

4.  Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice.

Authors:  Cheryl A Stoddart; Pheroze Joshi; Barbara Sloan; Jennifer C Bare; Philip C Smith; Graham P Allaway; Carl T Wild; David E Martin
Journal:  PLoS One       Date:  2007-11-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.